MP43-16 CREATION AND VALIDATION OF PURC ACTIVE SURVEILLANCE ELIGIBILITY (PURCASE) SCORE: AN EMPIRICALLY DERIVED SCORING SYSTEM FOR DETERMINING ACTIVE SURVEILLANCE ELIGIBILITY (2021)

You have accessJournal of UrologyProstate Cancer: Detection & Screening IV (MP43)1 Sep 2021MP43-16 CREATION AND VALIDATION OF PURC ACTIVE SURVEILLANCE ELIGIBILITY (PURCASE) SCORE: AN EMPIRICALLY DERIVED SCORING SYSTEM FOR DETERMINING ACTIVE SURVEILLANCE ELIGIBILITY Chintan Mehta, Cameron Rutledge, Matthew Loecher, Kaynaat Syed, John Danella, Serge Ginzburg, Laurence Belkoff, Jeffery Tomaszewski, Edouard Trabulsi, Eric Singer, Bruce Jacobs, Jay Raman, Thomas Guzzo, Robert Uzzo, and Adam Reese Chintan MehtaChintan Mehta More articles by this author , Cameron RutledgeCameron Rutledge More articles by this author , Matthew LoecherMatthew Loecher More articles by this author , Kaynaat SyedKaynaat Syed More articles by this author , John DanellaJohn Danella More articles by this author , Serge GinzburgSerge Ginzburg More articles by this author , Laurence BelkoffLaurence Belkoff More articles by this author , Jeffery TomaszewskiJeffery Tomaszewski More articles by this author , Edouard TrabulsiEdouard Trabulsi More articles by this author , Eric SingerEric Singer More articles by this author , Bruce JacobsBruce Jacobs More articles by this author , Jay RamanJay Raman More articles by this author , Thomas GuzzoThomas Guzzo More articles by this author , Robert UzzoRobert Uzzo More articles by this author , and Adam ReeseAdam Reese More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002064.16AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Active surveillance (AS) is the preferred management strategy for men with low risk prostate cancer. However, there are no universally accepted eligibility criteria to identify patients appropriate for AS, and proposed selection criteria are based mainly on expert opinion. This leads to variability in the patients selected for AS. We aimed to use data from a regional prostate cancer collaborative to create an evidence-based, simple scoring system to identify patients eligible for AS. METHODS: We identified men from Pennsylvania Urologic Regional Collaborative (PURC) with low or favorable intermediate risk disease as defined by the AUA, who underwent immediate radical prostatectomy (RP). Using logistic regression, we identified clinical variables associated with adverse pathology (AP) at RP (pathological grade group ≥3, pathologic stage ≥T3, or positive lymph nodes). This model was used to develop the PURC Active Surveillance Eligibility (PURCASE) score, with points assigned proportional to the z-value for each variable in the model. The PURCASE score was then validated using data from Michigan Urological Surgery Improvement Collaborative (MUSIC). RESULTS: The multivariable model of variables associated with adverse pathology, and the corresponding PURCASE score, are shown (T1). The PURCASE score ranges from 0-8, with higher scores indicating an increased risk of adverse pathology. Increasing PURCASE score was strongly associated with likelihood of adverse pathology. In both data sets, the PURCASE score outperformed the CAPRA score, AUA risk criteria, Johns Hopkins, and UCSF AS eligibility criteria in predicting rates of AP (T2). CONCLUSIONS: We developed the PURCASE score, an objective scoring system that can be used to identify potential candidates for prostate cancer active surveillance. This scoring system was developed using objective data, as opposed to expert opinion, and it appears to outperform several other risk stratification tools in selecting men for AS. Source of Funding: none © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e788-e788 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Chintan Mehta More articles by this author Cameron Rutledge More articles by this author Matthew Loecher More articles by this author Kaynaat Syed More articles by this author John Danella More articles by this author Serge Ginzburg More articles by this author Laurence Belkoff More articles by this author Jeffery Tomaszewski More articles by this author Edouard Trabulsi More articles by this author Eric Singer More articles by this author Bruce Jacobs More articles by this author Jay Raman More articles by this author Thomas Guzzo More articles by this author Robert Uzzo More articles by this author Adam Reese More articles by this author Expand All Advertisement PDF downloadLoading ...